Cellares defends its cell therapy platform after Bristol Myers ends partnership
read at Endpoints ↗Negative
Cellares, a cell therapy manufacturing startup, responded to criticism from Bristol Myers Squibb after the drugmaker terminated their agreement.
Bristol Myers withdrew, saying Cellares' commercial manufacturing technology did not meet its standards.
Cellares denied the allegation, asserting its technology is robust and the contract termination was unwarranted.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Cellares rebukes Bristol Myers' criticism of its cell therapy technology”
read at Endpoints ↗81 words · retrieved Aug 26
comments(0)
5-min edit window · permanent after that